Results 241 to 250 of about 184,582 (277)

The HIV Protease and Therapies for AIDS

1997
New, potent therapies for HIV disease are available, based on synthetic inhibitors of the viral protease, an essential viral enzyme. The results in clinical trials have been impressive with most treated individuals benefiting in terms of reduced quantity of detectable virus, enhanced numbers of CD4 lymphocytes and improvements in quality and duration ...
B D, Korant, C J, Rizzo
openaire   +2 more sources

Perspectives in HIV Protease Inhibitors

1996
The therapy of HIV-1, the causative agent of AIDS, is limited today to a small number of different drugs, all of which are nucleoside analogues. Nucleoside analogues active against HIV are all inhibitors of reverse transcriptase (RT) and target primarily early events in the replication cycle of HIV.
openaire   +2 more sources

HIV protease and its inhibition

The HIV protease (HPR) is a virus-specific aspartic protease responsible for processing the polyproteins of gag and gag-pol during virion maturation and for the proliferation of HIV. The activity of HPR is essential for virus infectivity, thus it is an important target for the development of anti-HIV drugs.
Rusconi, Stefano, Paoletti, Niccolò, Supuran, Claudiu T   +2 more
openaire   +2 more sources

Inhibitors of HIV-1 Protease

Journal of Enzyme Inhibition, 1992
The human immunodeficiency virus (HIV), the etiological agent for the acquired immune deficiency syndrome (AIDS), is a retrovirus which makes use of a virally-encoded aspartic protease to perform specific proteolytic processing of two of its gene products in order to form active enzymes and structural proteins within the mature virion.
openaire   +2 more sources

HIV-I protease

Applied Biochemistry and Biotechnology, 1996
A new method for obtaining HIV-I protease was suggested. Fusion proteins composed of the N-terminal fragment of human gamma-interferon and HIV-I protease connected with (Asp)4Lys (protein I) or Asp-Pro (protein II) linkers were expressed in Escherichia coli cells. The fusion proteins were produced as insoluble inclusion bodies in the 20% yield of total
N I, Dergousova, , Amerik AYu, A M, Volynskaya, L D, Rumsh   +3 more
openaire   +2 more sources

Assay of HIV Protease Dimerization

Biological Chemistry Hoppe-Seyler, 1992
B, Korant, C, Rizzo
openaire   +2 more sources

HIV protease inhibitors

Current Opinion in Infectious Diseases, 1997
Akhteruzzaman Molla, Anthony Japour
openaire   +3 more sources

HIV-1 protease inhibitors

Drug Discovery Today, 2001
openaire   +2 more sources

HIV Protease

2004
openaire   +1 more source

Inhibitors of HIV-1 Protease by Using In Situ Click Chemistry

Angewandte Chemie - International Edition, 2006
Hartmuth C Kolb, John Muldoon, Arthur J Olson   +2 more
exaly